Treatment of Li Fraumeni Syndrome

On 25 October 2006, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 404. The active ingredient is adenoviral vector containing human p53 gene for treatment of Li Fraumeni Syndrome.